Sonnet BioTherapeutics (SONN) Competitors $1.40 -0.03 (-2.10%) Closing price 05/1/2025 03:59 PM EasternExtended Trading$1.40 0.00 (0.00%) As of 05/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SONN vs. ALLR, LPCN, MIRA, CING, UPXI, GLYC, EDSA, COCP, BFRG, and UBXShould you be buying Sonnet BioTherapeutics stock or one of its competitors? The main competitors of Sonnet BioTherapeutics include Allarity Therapeutics (ALLR), Lipocine (LPCN), MIRA Pharmaceuticals (MIRA), Cingulate (CING), Upexi (UPXI), GlycoMimetics (GLYC), Edesa Biotech (EDSA), Cocrystal Pharma (COCP), Bullfrog AI (BFRG), and Unity Biotechnology (UBX). These companies are all part of the "pharmaceutical products" industry. Sonnet BioTherapeutics vs. Allarity Therapeutics Lipocine MIRA Pharmaceuticals Cingulate Upexi GlycoMimetics Edesa Biotech Cocrystal Pharma Bullfrog AI Unity Biotechnology Allarity Therapeutics (NASDAQ:ALLR) and Sonnet BioTherapeutics (NASDAQ:SONN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings. Does the media refer more to ALLR or SONN? In the previous week, Allarity Therapeutics and Allarity Therapeutics both had 3 articles in the media. Allarity Therapeutics' average media sentiment score of 0.79 beat Sonnet BioTherapeutics' score of 0.43 indicating that Allarity Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allarity Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sonnet BioTherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of ALLR or SONN? 11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 9.4% of Sonnet BioTherapeutics shares are held by institutional investors. 0.1% of Allarity Therapeutics shares are held by insiders. Comparatively, 2.0% of Sonnet BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has higher earnings and valuation, ALLR or SONN? Sonnet BioTherapeutics has higher revenue and earnings than Allarity Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllarity TherapeuticsN/AN/A-$11.90MN/AN/ASonnet BioTherapeutics$1M4.29-$7.44MN/AN/A Is ALLR or SONN more profitable? Allarity Therapeutics' return on equity of -369.67% beat Sonnet BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allarity TherapeuticsN/A -369.67% -100.06% Sonnet BioTherapeutics N/A -408.93%-174.13% Which has more risk & volatility, ALLR or SONN? Allarity Therapeutics has a beta of -0.06, indicating that its stock price is 106% less volatile than the S&P 500. Comparatively, Sonnet BioTherapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Do analysts rate ALLR or SONN? Sonnet BioTherapeutics has a consensus target price of $20.00, indicating a potential upside of 1,328.57%. Given Sonnet BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sonnet BioTherapeutics is more favorable than Allarity Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allarity Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sonnet BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor ALLR or SONN? Sonnet BioTherapeutics received 21 more outperform votes than Allarity Therapeutics when rated by MarketBeat users. Likewise, 84.62% of users gave Sonnet BioTherapeutics an outperform vote while only 50.00% of users gave Allarity Therapeutics an outperform vote. CompanyUnderperformOutperformAllarity TherapeuticsOutperform Votes150.00% Underperform Votes150.00% Sonnet BioTherapeuticsOutperform Votes2284.62% Underperform Votes415.38% SummarySonnet BioTherapeutics beats Allarity Therapeutics on 9 of the 13 factors compared between the two stocks. Get Sonnet BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SONN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SONN vs. The Competition Export to ExcelMetricSonnet BioTherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.29M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E RatioN/A7.3222.5118.54Price / Sales4.29241.49397.62103.30Price / CashN/A65.8538.1834.62Price / Book1.066.486.734.25Net Income-$7.44M$143.41M$3.22B$248.18M7 Day Performance2.19%2.58%1.38%1.03%1 Month Performance6.87%5.00%2.79%2.70%1 Year Performance-27.46%-3.72%15.41%4.05% Sonnet BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SONNSonnet BioTherapeutics1.3878 of 5 stars$1.40-2.1%$20.00+1,328.6%-24.7%$4.29M$1M0.0010Short Interest ↑Gap DownALLRAllarity Therapeutics0.298 of 5 stars$1.07-5.3%N/A-97.2%$18.21MN/A0.0010LPCNLipocine2.4887 of 5 stars$3.28+2.8%$10.00+204.9%-22.9%$17.55M$11.20M-4.3210Upcoming EarningsAnalyst ForecastNews CoverageMIRAMIRA Pharmaceuticals2.8513 of 5 stars$1.03-1.0%$14.00+1,259.2%+39.1%$17.32MN/A-1.842Short Interest ↓CINGCingulate2.5124 of 5 stars$4.35+1.2%$30.67+605.0%+313.5%$17.14MN/A-0.3020Short Interest ↑UPXIUpexi0.8244 of 5 stars$12.92-16.7%N/A+29.0%$17.07M$18.63M0.00130High Trading VolumeGLYCGlycoMimetics2.0954 of 5 stars$0.26-0.2%N/A-83.8%$16.81M$10,000.00-0.4450Upcoming EarningsAnalyst ForecastShort Interest ↓News CoverageEDSAEdesa Biotech3.0994 of 5 stars$2.40+1.7%$21.00+775.0%-47.4%$16.78MN/A-1.2820Upcoming EarningsShort Interest ↓Positive NewsGap DownCOCPCocrystal Pharma2.4848 of 5 stars$1.65-3.5%$7.00+324.2%+3.9%$16.78MN/A-0.8910Gap UpBFRGBullfrog AI0.4714 of 5 stars$1.77-4.3%N/A-42.7%$16.67M$60,000.00-2.084Upcoming EarningsShort Interest ↑UBXUnity Biotechnology4.1223 of 5 stars$0.98+0.4%$5.33+443.8%-29.5%$16.54M$240,000.00-0.7560News Coverage Related Companies and Tools Related Companies Allarity Therapeutics Competitors Lipocine Competitors MIRA Pharmaceuticals Competitors Cingulate Competitors Upexi Competitors GlycoMimetics Competitors Edesa Biotech Competitors Cocrystal Pharma Competitors Bullfrog AI Competitors Unity Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SONN) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonnet BioTherapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonnet BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SONN Stock Free SONN Stock Alerts